Dyne Therapeutics, Inc. (DYN) Stock
6 of the hedge funds AlphaScala tracks reported DYN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $33.07M. Company insiders reported 1 open-market buy and 17 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own DYN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 1.49M | $33.07M | +1691% |
| Citadel Ken Griffin | 1.14M | $25.41M | +469% |
| Millennium Management Israel Englander | 432K | $9.59M | +172% |
| Renaissance Technologies Jim Simons (founder) | 361K | $8.01M | -32% |
| D.E. Shaw David Shaw | 60K | $1.34M | NEW |
| Blackstone | 23K | $501.5K | -60% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Dyne Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 2, 26 | Posner Brian S | Director | BUY | 2.5K | $40K |
| Sep 8, 26 | Cox John | CEO & President | SELL | 5.7K | $107K |
| Sep 8, 26 | Kerr Douglas | Chief Medical Officer | SELL | 1.3K | $24K |
| Sep 8, 26 | Friedl-Naderer Johanna | Chief Commercial Officer | SELL | 185 | $3K |
| Sep 4, 26 | Kerr Douglas | Chief Medical Officer | SELL | 3.7K | $91K |
| Sep 4, 26 | Friedl-Naderer Johanna | Chief Commercial Officer | SELL | 900 | $22K |
| Aug 14, 26 | Rhodes Jason P | Director | SELL | 1.36M | $34.0M |
| Aug 14, 26 | Rhodes Jason P | Director | SELL | 478.4K | $12.0M |
| Aug 14, 26 | Rhodes Jason P | Director | SELL | 322.5K | $8.1M |
| Aug 13, 26 | Cox John | CEO & President | SELL | 5.0K | $131K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →DYN price chart
Powered by TradingViewWhat does Dyne Therapeutics, Inc. do?
Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to deliver targeted RNA therapies designed to overcome delivery limitations to muscle tissue and the central nervous system. Dyne's lead programs address significant unmet medical needs in conditions including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company is advancing multiple candidates through clinical development, with key programs progressing toward regulatory milestones and potential commercialization. Dyne operates in the rare disease biotechnology space, serving patients with limited treatment options and positioning itself for potential market entry as its pipeline candidates mature toward approval and launch.